SCHEMBL4101857

SCHEMBL4101857

O=C(O)c1cc(NCCc2cccc(C(F)(F)F)c2F)ccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 3/20 0.52
KDM4C Q9H3R0 4/20 0.47
EGFR P00533 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
RGS12 O14924 1/20 0.46
LCK P06239 1/20 0.46
CAMKK2 Q96RR4 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PPARA Q07869 1/20 0.46
STING1 Q86WV6 1/20 0.46
GAA P10253 1/20 0.44
CD38 P28907 1/20 0.41
CFTR P13569 1/20 0.39
CNR1 P21554 1/20 0.39
RORC P51449 1/20 0.39
MCL1 Q07820 1/20 0.39
CDK2 P24941 1/20 0.39
MEN1 O00255 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30473064 1.00 NOX4 (0.52) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL4093950 0.89 NOX4 (0.59) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL4100274 0.82 PPARA (0.52) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL608267 0.82 PPARA (0.52) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL29391362 0.82 PPARA (0.52) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL610770 0.78 NOX4 (0.47) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL29388037 0.78 NOX4 (0.47) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL4097800 0.78 PPARA (0.52) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL4095655 0.78 PPARA (0.52) NOX4KDM4CEGFRALDH1A1MAPT
SCHEMBL608266 0.77 NOX4 (0.61) NOX4KDM4CEGFRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12285402-B2 Compositions and methods for treating pulmonary disorders GNT PHARMA CO., LTD. (KR) 2025-04-29 US disclosed
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS GNT PHARMA CO., LTD. (KR) 2023-07-27 US disclosed
US-20120301551-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2012-11-29 US disclosed
US-20090149542-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2009-06-11 US disclosed
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149542-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION BCL2, BAX, SMN1; SMN2 NOX4 2363/4885KDM4C 3544/4885EGFR 2671/4885
US-20120301551-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION BCL2, BAX, SMN1; SMN2 NOX4 2363/4885KDM4C 3544/4885EGFR 2671/4885
US-20230233503-A1 COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERS HAO2, ACOX1, HAO1 NOX4 195/4885KDM4C 3145/4885EGFR 3946/4885
US-12285402-B2 Compositions and methods for treating pulmonary disorders HAO2, ACOX1, HAO1 NOX4 195/4885KDM4C 3145/4885EGFR 3946/4885
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction BCL2, BAX, SMN1; SMN2 NOX4 2363/4885KDM4C 3544/4885EGFR 2671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.